ATE366308T1 - Immunostimulierende oligodeoxyribonuklein moleküle - Google Patents

Immunostimulierende oligodeoxyribonuklein moleküle

Info

Publication number: ATE366308T1
Authority: AT; Austria
Prior art keywords: deoxyribosepurine; deoxycytosine; deoxyinosine; deoxyguanosine; deoxyadenosine
Prior art date: 2001-05-21

Application number

AT02748709T

Other languages

English (en)

Inventor

Karen Lingnau

Carola Schellack

Walter Schmidt

Original Assignee

Intercell Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-21

Filing date

2002-05-17

Publication date

2007-07-15

2002-05-17 Application filed by Intercell Ag filed Critical Intercell Ag

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE366308T1 publication Critical patent/ATE366308T1/de

Links

230000003308 immunostimulating effect Effects 0.000 title abstract 2
RPFPNGBGDKGFRI-XLPZGREQSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 RPFPNGBGDKGFRI-XLPZGREQSA-N 0.000 abstract 2
FERYXNKLCFJNMG-QJPTWQEYSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 FERYXNKLCFJNMG-QJPTWQEYSA-N 0.000 abstract 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 1
COVHWGAKPGOZBI-QJPTWQEYSA-N [(2r,3s,5r)-3-hydroxy-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 COVHWGAKPGOZBI-QJPTWQEYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000004712 monophosphates Chemical class 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
229940046166 oligodeoxynucleotide Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Laminated Bodies (AREA)

AT02748709T 2001-05-21 2002-05-17 Immunostimulierende oligodeoxyribonuklein moleküle ATE366308T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT8052001		2001-05-21
PCT/EP2002/005448 WO2002095027A2 (en)	2001-05-21	2002-05-17	Immunostimulatory oligodeoxynucleic molecules

Publications (1)

Publication Number	Publication Date
ATE366308T1 true ATE366308T1 (de)	2007-07-15

Family

ID=3681210

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02748709T ATE366308T1 (de)	2001-05-21	2002-05-17	Immunostimulierende oligodeoxyribonuklein moleküle

Country Status (10)

Country	Link
US (2)	US20050070462A1 (de)
EP (2)	EP1390494A2 (de)
JP (2)	JP4188092B2 (de)
CN (1)	CN1526016A (de)
AT (1)	ATE366308T1 (de)
AU (1)	AU2002320762B2 (de)
CA (2)	CA2447793A1 (de)
DE (1)	DE60221004T2 (de)
ES (1)	ES2288555T3 (de)
WO (2)	WO2002094845A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7378234B2 (en)	2002-09-13	2008-05-27	Intercell Ag	Method for isolating hepatitis C virus peptides
US7528223B2 (en)	2002-07-24	2009-05-05	Intercell Ag	Antigens encoded by alternative reading frames from pathogenic viruses
US7704514B2 (en)	2003-03-24	2010-04-27	Intercell Ag	Vaccines

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002358616A1 (en) *	2001-12-07	2003-06-17	Intercell Ag	Immunostimulatory oligodeoxynucleotides
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
DE102004049223A1 (de)	2004-10-08	2006-04-20	Johannes-Gutenberg-Universität Mainz	Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
JP2007045730A (ja) *	2005-08-09	2007-02-22	Nitto Denko Corp	免疫誘導能増強方法
EP1924284A1 (de) *	2005-09-14	2008-05-28	Hartmann, Gunther	Zusammensetzungen mit immunstimulatorischen rna-oligonucleotiden und verfahren zur herstellung dieser rna-oligonucleotide
EP2292644A3 (de)	2006-07-07	2011-05-25	Intercell AG	Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
JP2010503384A (ja)	2006-09-15	2010-02-04	インターセルアーゲー	ボレリア（Ｂｏｒｒｅｌｉａ）抗原
EP1923069A1 (de)	2006-11-20	2008-05-21	Intercell AG	Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
CA2675379A1 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
CN102015754A (zh)	2007-05-02	2011-04-13	英特塞尔股份公司	克雷伯菌（Klebsiella）抗原
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
EP2012122A1 (de)	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
CN101883782A (zh)	2007-06-18	2010-11-10	英特塞尔股份公司	衣原体抗原
AU2009226949A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
ES2569907T3 (es)	2008-06-27	2016-05-13	Zoetis Services Llc	Composiciones adyuvantes novedosas
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de)	2009-02-13	2012-01-18	Intercell AG	Nicht typisierbare haemophilus influenza-antigene
EP2319871A1 (de)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
KR20120089863A (ko)	2009-10-09	2012-08-14	사노피	“개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
EP2308896A1 (de)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
JP5808082B2 (ja) *	2010-04-30	2015-11-10	株式会社Adeka	細胞への水溶性高分子量物質の導入方法及び導入剤
PL2753352T5 (pl)	2010-09-03	2022-10-17	Valneva Austria Gmbh	Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
UA130246C2 (uk)	2013-09-19	2025-12-31	Зоетіс Сервісіз Ллс	Ад'ювант на основі олії
KR20220068276A (ko) *	2013-09-20	2022-05-25	고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼	면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도
CN115317600A (zh)	2015-01-16	2022-11-11	硕腾服务有限责任公司	口蹄疫疫苗
AU2019220386A1 (en)	2018-02-16	2020-08-20	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (de)	2018-02-16	2019-08-21	2A Pharma AB	Mutiertes parvovirus-strukturprotein
EP3972639A1 (de)	2019-05-20	2022-03-30	Valneva SE	Subunit-impfstoff zur behandlung oder vorbeugung einer atemwegsinfektion
EP3980056A4 (de)	2019-05-31	2023-03-29	Universidad De Chile	Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
EP4058056A1 (de)	2020-10-07	2022-09-21	Valneva Sweden AB	Cholera-impfstoffformulierung
KR20230167017A (ko)	2021-04-09	2023-12-07	발네바 에스이	인간 메타뉴모 바이러스 백신
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725545A (en) *	1971-02-03	1973-04-03	R Maes	Enhancement of antibody production by nucleic acid-polycation complexes
US3906092A (en) *	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167379A3 (de)	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
ATE292980T1 (de)	1996-10-11	2005-04-15	Univ California	Immunostimulierende oligonucleotidekonjugate
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da)	1997-03-10	2010-01-04	Ottawa Hospital Res Inst	Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (de)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP1003850B1 (de)	1997-06-06	2009-05-27	The Regents of the University of California	Inhibitoren von immunstimulatorischen dna sequenz aktivität
AU760549B2 (en)	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
US6403102B1 (en) *	1998-10-29	2002-06-11	Connaught Laboratories Limited	Chlamydia antigens and corresponding DNA fragments and uses thereof
AT408721B (de) *	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
AU5736601A (en) *	2000-05-01	2001-11-12	Hybridon Inc	Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
RU2413520C2 (ru)	2000-06-08	2011-03-10	Интерселл Аг	Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
ES2307568T3 (es)	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
AU2002358616A1 (en)	2001-12-07	2003-06-17	Intercell Ag	Immunostimulatory oligodeoxynucleotides

2002
- 2002-05-17 WO PCT/EP2002/005447 patent/WO2002094845A2/en not_active Ceased
- 2002-05-17 EP EP02745299A patent/EP1390494A2/de not_active Withdrawn
- 2002-05-17 AU AU2002320762A patent/AU2002320762B2/en not_active Ceased
- 2002-05-17 CA CA002447793A patent/CA2447793A1/en not_active Abandoned
- 2002-05-17 AT AT02748709T patent/ATE366308T1/de active
- 2002-05-17 US US10/478,426 patent/US20050070462A1/en not_active Abandoned
- 2002-05-17 JP JP2002592489A patent/JP4188092B2/ja not_active Expired - Fee Related
- 2002-05-17 ES ES02748709T patent/ES2288555T3/es not_active Expired - Lifetime
- 2002-05-17 JP JP2002591518A patent/JP2005501004A/ja not_active Withdrawn
- 2002-05-17 US US10/478,771 patent/US7858588B2/en not_active Expired - Fee Related
- 2002-05-17 CA CA002448031A patent/CA2448031A1/en not_active Abandoned
- 2002-05-17 EP EP02748709A patent/EP1390495B1/de not_active Expired - Lifetime
- 2002-05-17 DE DE60221004T patent/DE60221004T2/de not_active Expired - Lifetime
- 2002-05-17 CN CNA028116976A patent/CN1526016A/zh active Pending
- 2002-05-17 WO PCT/EP2002/005448 patent/WO2002095027A2/en not_active Ceased

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7528223B2 (en)	2002-07-24	2009-05-05	Intercell Ag	Antigens encoded by alternative reading frames from pathogenic viruses
US7378234B2 (en)	2002-09-13	2008-05-27	Intercell Ag	Method for isolating hepatitis C virus peptides
US7704514B2 (en)	2003-03-24	2010-04-27	Intercell Ag	Vaccines
US8784837B2 (en)	2003-03-24	2014-07-22	Valneva Austria Gmbh	Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

Also Published As

Publication number	Publication date
CN1526016A (zh)	2004-09-01
WO2002094845A2 (en)	2002-11-28
US7858588B2 (en)	2010-12-28
WO2002094845A3 (en)	2003-11-06
ES2288555T3 (es)	2008-01-16
EP1390494A2 (de)	2004-02-25
DE60221004D1 (de)	2007-08-16
US20050070462A1 (en)	2005-03-31
JP4188092B2 (ja)	2008-11-26
CA2448031A1 (en)	2002-11-28
WO2002095027A2 (en)	2002-11-28
AU2002320762B2 (en)	2006-09-21
DE60221004T2 (de)	2008-03-13
WO2002095027A3 (en)	2003-08-21
CA2447793A1 (en)	2002-11-28
EP1390495A2 (de)	2004-02-25
JP2004530428A (ja)	2004-10-07
US20040248831A1 (en)	2004-12-09
EP1390495B1 (de)	2007-07-04
JP2005501004A (ja)	2005-01-13

Publication	Publication Date	Title
ATE366308T1 (de)	2007-07-15	Immunostimulierende oligodeoxyribonuklein moleküle
ATE249839T1 (de)	2003-10-15	Immunstimulierende oligodeoxynukleotide
ATE292638T1 (de)	2005-04-15	Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside
CY1116876T1 (el)	2017-04-05	Ολιγονουκλεοτιδικα αναλογα που ενσωματωνουν 5-αζα-κυτοσινη σε αυτα
ES2141953T3 (es)	2000-04-01	Composiciones de adhesivos sensibles a la presion de poli(beta-hidroxiorganoato).
DE60017259D1 (de)	2005-02-10	Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden
ES2118593T3 (es)	1998-09-16	Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
BRPI0512110A (pt)	2007-10-23	multìmeros de oligonucleotìdeos imunoestimulatórios
BR0211926A (pt)	2006-12-12	agentes para realçar a resposta imune
BR9813391A (pt)	2000-10-10	Composição de epo, preparado farmacêutico e processos para produzir uma composição de epo e para aumentar a atividade especìfica de uma composição de epo
HUP0203914A2 (en)	2003-03-28	High order nucleic acid based structures
Okamura et al.	2019	Proto‐urea‐RNA (Wöhler RNA) containing unusually stable urea nucleosides
PT1098893E (pt)	2003-08-29	Composto ciclicos uteis n tratamento da dislipidemia, aterosclerose e diabetes, composicoes farmaceuticas e processo de preparacao
CY1106041T1 (el)	2011-04-06	Καινοφανης συλλεκτινη
DE69920247D1 (de)	2004-10-21	Veränderung der dns methyltransferase durch kombinationstherapie
WO2023039005A3 (en)	2023-07-20	Modified short interfering nucleic acid (sina) molecules and uses thereof
BR9610905A (pt)	1999-07-13	Derivados de sulfamato processo de fabricação de derivados de sulfamato e composições farmacêuticas
BR0312460A (pt)	2005-04-26	Suporte sólido, processo de preparação, e, uso do mesmo
DK1644389T3 (da)	2011-05-09	Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
JP2003012760A5 (de)	2008-02-07
ATE242261T1 (de)	2003-06-15	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
CA2360069A1 (en)	2000-07-20	Protecting groups for carbohydrate synthesis
KR960700262A (ko)	1996-01-19	이합체 블록의 합성 및 그것의 올리고누클레오티드 어셈블리에의 사용 방법(synthesis of dimmer blocks and their use in assembling oligonucleotides)
DE60204859D1 (de)	2005-08-04	Verfahren zur herstellung von 2'-fluoro-beta-l-arabinofuranosylnukleosiden
Hartel et al.	2000	Substitution of Adenine by Purine‐2, 6‐diamine Improves the Nonenzymatic Oligomerization of Ribonucleotides on Templates Containing Thymidine